CELZ shakes off morning profit takers and goes gre
Post# of 350
Dr. Tomas Ichim from the board of CELZ (Creative Medical Technology)
Dr. Ichim has taken several cell therapies to FDA clearance and clinical trials. The Company is currently preparing an Investigational New Drug (IND) application with the FDA for use of its AmnioStem™ stem cell product for treatment of radiation toxicity through its neurology focused subsidiary CerebroStem LLC and its Medical Director, Santosh Kesari, MD, Ph.D, FANA, FAAN, Chair and Professor, Department of Translational Neurosciences and Neurotherapeutics, John Wayne Cancer Institute, as well as Director of Neuro-Oncology, Providence Saint John's Health Center and leads the Pacific Neuroscience Research Center at Pacific Neuroscience Institute.
The AmnioStem™ stem cell is covered by an issued US Patent that was exclusively licensed from the University of California by the Company in 2016.
Creative Medical Technology Holdings, Inc. is a commercial stage biotechnology company currently trading on the OTCQB under the ticker symbol CELZ. For further information about the company go to www.creativemedicaltechnology.com.
Follow for the latest news on Twitter: @stockguru2018
UHLN hot today!!! Happy Green Friday!!!